Publications by authors named "A V Holden"
Results of SurVeil Versus IN.PACT Admiral Paclitaxel Coated Balloons in Femoropopliteal Arteries: Outcomes of the Randomised TRANSCEND Study Through 24 Months.
Eur J Vasc Endovasc Surg
November 2024
Article Synopsis
- * In this randomized controlled trial involving 446 patients, the SurVeil PCB showed a primary safety rate of 91.8% and a primary efficacy rate of 82.2%, while the IN.PACT Admiral had rates of 89.8% and 85.9%, respectively.
- * The results indicate that the SurVeil PCB is a safe and effective treatment option, demonstrating non-inferiority to the IN.PACT Admiral PCB over a 24-month period.
Purpose: Little is known about dentists' preparedness in managing oral side effects in patients undergoing cancer therapy (CTx). The purpose of this systematic review is to identify barriers and facilitators of dentists in managing oral health of cancer patients (CPs).
Methods: The review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was Prospero registered (CRD42022333055).
Purpose: Intravascular lithotripsy (IVL) has shown promising safety and effectiveness in calcified peripheral artery disease (PAD) in large trials and small real-world experiences. Real-world evidence from a larger cohort is lacking, so we aimed to evaluate the real-world acute performance of IVL in the treatment of calcified PAD.
Materials And Methods: The Disrupt PAD III Observational Study (OS) is a prospective, multicenter, single-arm study.
Article Synopsis
- The study explores how a sensory support intervention (SSI) program impacts quality of life in individuals with mild-to-moderate dementia who also have hearing and vision difficulties.
- Researchers conducted a randomized controlled trial across seven clinics in five European countries, evaluating the effectiveness of an 18-week program compared to standard care.
- The primary outcome measured was changes in health-related quality of life, using the Dementia Quality of Life Instrument (DEMQoL), with a total of 252 participants randomly assigned to either the SSI group or a control group receiving usual care.